Entropy Neurodynamics (ASX:ENP) Begins Cohort 2 Dosing with Shorter TRP-8803 Infusion

Aditi Sarkar

07 October 2026 03:41 PM AEDT

Entropy Neurodynamics (ASX:ENP) Begins Cohort 2 Dosing with Shorter TRP-8803 Infusion

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

The first Cohort 2 patient completed a 60-minute TRP-8803 infusion on 5 October 2026.
Cohort 2 tests a shorter infusion of 60 minutes, compared with 140 minutes in Cohort 1.
All six Cohort 2 patients are enrolled, with topline results expected by the end of 2026.
Cohort 1 reported a 73% reduction in weekly binge-eating episodes at 12 weeks.

Entropy Neurodynamics Limited (ASX:ENP) announced on 7 October 2026 that the first patient in Cohort 2 of its Phase 2 Binge Eating Disorder (BED) study has completed a 60-minute infusion of TRP-8803. The infusion took place on Monday, 5 October 2026, and the patient was safely discharged after all post-treatment assessments.

Cohort 2 Design

Cohort 2 is testing whether the infusion period can be reduced from 140 minutes, as used in Cohort 1, to 60 minutes. The cohort is fully recruited with six patients enrolled, and topline results are expected by the end of 2026.

The first patient reported a maximum intensity of 9 out of 10 on the protocol-defined psychedelic intensity measure.

Cohort 1 Results

At the 12-week follow-up, all six treatment-resistant patients in Cohort 1 showed clinically meaningful improvement in BED symptoms, and 50% achieved remission. Weekly binge-eating episodes fell by 73% from baseline.

Three of the six patients reported no binge-eating episodes throughout the 84-day follow-up. Quality of life improved by 61%, with sustained reductions in anxiety and depression symptoms.

Why a Shorter Infusion Matters

The company said a shorter treatment time aims to reduce the time required from healthcare professionals, lower treatment-room requirements and increase patient throughput. This is intended to make the therapy more practical to scale in clinical settings.

CEO Jason Carroll said the successful completion of the first 60-minute infusion is an important milestone for TRP-8803.

Key Takeaways

The first 60-minute TRP-8803 infusion in Cohort 2 was completed on 5 October 2026.
Cohort 2 is fully enrolled, with topline results due by the end of 2026.
Cohort 1 showed a 73% fall in weekly binge-eating episodes and 50% remission.
A shorter infusion could improve the practicality of the treatment in clinics.

FAQs

Q: What is TRP-8803?

A:It is Entropy Neurodynamics' infusion-based treatment being studied in a Phase 2 binge eating disorder trial.

Q: What milestone was reported?

A:The first Cohort 2 patient completed a 60-minute TRP-8803 infusion and was safely discharged.

Q: How does Cohort 2 differ from Cohort 1?

A:It tests a 60-minute infusion compared with 140 minutes in Cohort 1.

Q: What did Cohort 1 show?

A:A 73% reduction in weekly binge-eating episodes, with 50% of patients achieving remission.

Q: When are Cohort 2 results expected?

A:Topline results are expected by the end of 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.